Seize the Moment: Lock in Pre-Market Gains for Maximum Profit!

Don’t want emails from us anymore? Click here to unsubscribe

Hello Part-time Trader…👋

Premium Stock Alerts is here with your pre-market cheat sheet. In today's issue, we delve into:

  • Fed's Latest Announcements: Understand the Federal Reserve's recent decisions and economic outlook, and how they might influence the markets.

  • Volume Anomalies: Identify stocks witnessing unusual trading volumes, pointing to potential opportunities or risks.

  • Top Pre-Market Movers: Identify early winners poised for a strong market opening.

  • Market Indices & Sector Overview: Get a snapshot of key market indices and sector performances to gauge the day's potential trends.

  • FDA Approvals & Upcoming Decisions: Keep an eye on the latest FDA approvals and crucial upcoming decisions affecting biotech and pharmaceutical stocks.

Now, let's dive into today's edition for a closer look at the insights and analysis that will shape your trading decisions.


5 Must-Buy Stocks to Electrify Your Portfolio in 2024!

Unlock the secret to wealth with our expert-curated Power-List! Discover 5 undervalued stocks poised for explosive growth. Act now to transform your portfolio and secure your financial future. 

Time is ticking - access your free list TODAY!

Happening Today

✓ 08:30 AM ET – Chicago Fed National Activity (Mar)

✓ 11:30 AM ET – 3-Month Bill Auction

✓ 11:30 AM ET –  6-Month Bill Auction


The NASDAQ 100 takes a tumble while the Dow Jones edges up, amidst a mixed sentiment in the stock futures market.



⬇️ -0.87% 



⬆️ 0.55% 



⬇️ -2.05%


Financials drive upward momentum as Consumer Discretionary wanes, with Information Technology facing a substantial downturn.




Consumer Discretionary


-1.19% 🔴

Consumer Staples


+0.95% 🟢



+1.12% 🟢



+1.35% 🟢

Health Care


+0.32% 🟢



-0.19% 🔴



-0.11% 🔴

Real Estate


+0.40% 🟢

Information Technology


-3.08% 🔴

Communication Services


-2.03% 🔴



+1.47% 🟢


Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation

Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.

Analyze Any Stock Free

Unusual Volume

📈 Next.e.GO N.V. (EGOX) jumped 42.22% to $0.05 on a whopping 330.91 million shares traded.

📈 Investors went wild, sending AGBA Group Holding Limited (AGBA) stock soaring 21.36% to $1.25 on a massive volume of 128.09 million shares after the company announced $4 billion merger agreement with Triller Corp.

📈 Abnormal activity shook SINTX Technologies Inc (SINT), pushing it up 4.50% to $0.04 on a whopping 107.71 million shares traded.

📈 Blue Star Foods Corp (BSFC) stock recently closed 18.01% upper at $0.08 on substantial volume of 92.28 million shares. This unusual activity came after the company announced that it has secured additional funding to help meet increased demand under its previously announced Master Service Agreement as well as increase the volume in its soft shell crab operations.

📈 Ault Alliance Inc (AULT) increase by 25.57% in a single trading session, with abnormally high trading volume of 56.52 million shares after reporting that it has received an investment of $44 million to date from Ault & Company under the November 2023 Securities Purchase Agreement.


#1 Stock To Buy Now

This report reveals the name of this little-known stock poised to soar in the months ahead. Act Fast - once this stock hits the media the biggest profits could be gone.

Get This Stock Now

Premarket Movers

Moolec Science SA (MLEC) experiences a substantial 121.73% surge in pre-market trading following the receipt of USDA approval for plant-grown animal proteins.

SuperCom Ltd. (SPCB) sees a significant 27.36% increase, reaching a pre-market price of $0.28 after reporting 51% annual revenue growth, non-GAAP EPS of $0.47 and 5-year-record EBITDA of $4.8 million for full year 2023.

Complete Solaria, Inc. (CSLR) demonstrates a noteworthy 47.22% surge, with a pre-market price of $0.66. The company released an updated version of its internal memo detailing the short attack on Complete Solaria last Monday, April 15, with new information on last Friday’s 16.6 million share buying spree by retail investors.

Pre Market Gainers

Pre Market Change

Pre Market Volume
































Free Stock Analysis Report: Shows You when to Buy or Sell Stocks

Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.

Analyze Any Stock Free

Important FDA 

Recently Announced

On April 5, 2024, Johnson & Johnson (JNJ) reached a significant milestone as the FDA granted expanded authorization for their treatment Carvykti. This extension broadens Carvykti's application to include adult patients with relapsed or refractory multiple myeloma who have previously undergone at least one line of therapy.

AbbVie (ABBV) achieved a noteworthy accomplishment on the same date. Their drug ELAHERE, which previously received accelerated approval, has now attained full FDA approval for treating specific ovarian cancer patients.

April 5, 2024, marked a momentous occasion for Bristol-Myers Squibb Co. (BMY) with the FDA's endorsement of Opdivo. Opdivo, in combination with cisplatin-based chemotherapy, is now established as a primary treatment option for adult patients facing unresectable or metastatic urothelial carcinoma.

Upcoming Announcements

ImmunityBio, Inc. (IBRX) has its focus fixed on April 23, 2024. This is the pivotal date when the FDA is slated to unveil its decision regarding N-803 plus BCG, a potential groundbreaking therapy for high-risk non-muscle-invasive bladder cancer. The company's resubmitted Biologics License Application (BLA) carries significant promise for patients grappling with this formidable condition.

Aquestive Therapeutics Inc. (AQST) stands at the brink of a transformative development. April 28, 2024, marks the day when the FDA will render its judgment on Libervant, a prospective remedy for seizure clusters in young children. This New Drug Application (NDA) submission could bridge a crucial gap in pediatric epilepsy treatment, and the company eagerly awaits the regulatory decision.

PharmaTher Holdings Ltd. (PHRRF.OB) holds its breath until April 29, 2024. This is the momentous occasion when the FDA will pass judgment on KETARX, a versatile drug with potential applications in anesthesia, sedation, pain management, mental health, and neurological disorders. A favorable Abbreviated New Drug Application (ANDA) decision could unlock novel therapeutic avenues across multiple treatment domains, and the company awaits the outcome with bated breath.

Happy investing,

Maeve Grace
Editor In Chief
Premium Trade Alerts

Important: This newsletter does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.

Disclosure: I hold no positions in any companies mentioned, either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.

Join the conversation

or to participate.